1. Home
  2. AKBA vs MRBK Comparison

AKBA vs MRBK Comparison

Compare AKBA & MRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

Logo Meridian Corporation

MRBK

Meridian Corporation

HOLD

Current Price

$19.81

Market Cap

235.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
MRBK
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
251.0M
235.5M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
AKBA
MRBK
Price
$1.22
$19.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$4.67
$20.75
AVG Volume (30 Days)
4.1M
140.5K
Earning Date
05-07-2026
04-23-2026
Dividend Yield
N/A
3.05%
EPS Growth
93.94
30.34
EPS
N/A
0.17
Revenue
N/A
$6,316,000.00
Revenue This Year
N/A
$25.40
Revenue Next Year
N/A
$8.15
P/E Ratio
N/A
$116.41
Revenue Growth
N/A
10.13
52 Week Low
$0.82
$13.81
52 Week High
$3.81
$21.59

Technical Indicators

Market Signals
Indicator
AKBA
MRBK
Relative Strength Index (RSI) 46.66 51.87
Support Level $1.16 $18.42
Resistance Level $1.52 $20.72
Average True Range (ATR) 0.07 0.55
MACD -0.02 -0.06
Stochastic Oscillator 7.59 43.62

Price Performance

Historical Comparison
AKBA
MRBK

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About MRBK Meridian Corporation

Meridian Corp is a bank holding company based in the United States. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal and business lending and deposit services. It operates in three reportable segments, including Bank, Wealth, and Mortgage. Meridian generates maximum revenue from the Bank segment, which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans. Geographically, it operates in Pennsylvania, New Jersey, and Delaware, as well as in the Central Maryland market and southwest Florida, U.S.

Share on Social Networks: